Cancer, when detected at an early stage, has a very good probability of being eradicated by surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates of cure without the side effects of radical therapy. We report on the results of our clinical experience with photodynamic therapy (PDT) for the treatment of early carcinomas in the upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Sixty-four patients with 101 squamous cell carcinomas were treated with three different photosensitizers:
INTRODUCTION
Patients with head and neck cancer are at high risk of developing additional synchronous and metachronous primary tumors, not only in the upper aerodigestive tract, but also in the esophagus and the tracheobronchial tree [1] [2] [3] [4] [5] . This phenomenon is attributed to the "field cancerization" concept, which suggests that the long-term carcinogen exposure leads to multiple genetic mutations throughout 146 A. RADU et al.
the aerodigestive tract epithelium [6, 7] . Although still a debatable issue, thorough pretherapy screening and systematic follow-up of these patients allow the detection of a great number of second primary tumors at an early stage, i.e. in situ or microinvasive [4] . Treating these early tumors with a nonmutilating and minimally invasive therapeutic modality should be highly beneficial in patients with head and neck cancer who are often in poor general condition due to a previous radical procedure directed towards the primary tumour or to concomitant diseases of the heart, lung or liver.
Photodynamic therapy (PDT), which is based on the combined effects of a photosensitizing drug and visible light, has the potential to cure such early cancers [8] [9] [10] [11] [12] [13] [14] [15] . This relatively new therapeutic modality has the distinct advantage that it can be repeated multiple times without inducing any resistance or cumulative toxicity [16] . Photodynamic therapy can also be utilized in association with other procedures, and it does not preclude the use of eventual more aggressive future treatments in case of failure.
Since 1984, we have investigated PDT for the treatment of early squamous cell carcinoma arising in the upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Three different photosensitizers were used: hematoporphyrin derivative (HPD), Photofrin II, and tetra(m-hydroxyphenyl)-chlorin (mTHPC). The mTHPC, a second generation photosensitizer, was introduced in our study in 1992, because in preclinical studies it appeared to be superior to HPD and Photofrin II in terms of chemical purity, phototoxicity, and duration of skin photosensitization [17, 18] . This In all cases, the size of the illumination area was larger than the extent of the tumour. The reason for the broad range oflight doses applied is that in some cases, the light dose was adapted according to the photosensitizer fluorescence signal measured onto the tumour just before irradiation [25] . In the head and neck field, the esophagus, and the bronchi, PDT has been applied in both superficial and invasive malignancies [26] [27] [28] [29] [30] [31] . However, the use of PDT to palliate advanced lesions has shown only moderate advantages compared to other methods such as thermal YAG laser vaporization or endoprothesis [32, 33] . Although PDT temporarily reduces the volume of invasive tumors, its benefit is limited by the severe complications, such as haemorrhage and perforation, related to the procedure [30, 34] . Thus, the main interest in using PDT is the cure of superficial cancers. This technique has been successfully employed for early malignancies in the oral cavity, the pharynx, the gastrointestinal tract and the tracheobronchial tree [35] [36] [37] [38] [39] [40] [41] .
The results of our study confirm that PDT is an efficient treatment for in situ and micro-invasive squamous cell carcinomas of the UAT, the esophagus, and the tracheobronchial tree. We have treated more than 100 early tumors and have achieved a complete response in 76% of them, with a mean disease-free follow-up of 27 months. In most cases, In our study, all but one major complication occurred following red light illumination. Esophageal perforation with esophagotracheal or esophagomediastinal fistula formation after PDT for invasive cancers has been previously reported [30, 44] . These complications are most often related to the extensive necrosis generated by the treatment.
However, in the case of early carcinomas, transmural necrosis after PDT is the result of the lack of true selectivity of the photosensitizer's distribution between the tumour and the underlying healthy tissue [11, [45] [46] [47] . Thus, as the red light penetrates deeply into the tissues, illumination at 630 or 652 nm in the esophagus may not only cause destruction of the early cancer but also of the smooth muscle layers underneath with subsequent perforation of the esophageal wall. Irradiation with green light, which acts more superficially [48] , tends to compensate the poor selectivity of the dyes. Since [49] . In the superficial bronchial cancers as defined here, where by definition the cartilage is not invaded, a transmural necrosis with perforation and fistula formation following PDT is very unlikely to occur. As the bronchial cartilage accumulates only minimal amounts of photosensitizers [50] , red light illumination can be safely used. The insufficient therapeutic selectivity of the dyes is underlined by the occurrence in our study of two esophageal stenoses. Even though the tumour to be treated was not circular, a 360 illumination induced a circumferential necrosis that caused a subsequent stricture. Therefore, the application of 180 or 240 windowed light distributors in our study has limited the extent of tissue damage and has prevented the development of further esophageal stenoses.
Our study confirms that PDT is an effective modality for the treatment of early cancer in the UAT, the bronchi, and the esophagus. In addition, the use of optimal light dosimetry with adequate light diffusers renders PDT safer. However, development of new photosensitizers with increased selectivity and limited skin photosensitization, as well as improvement of the light delivery systems should contribute to the expansion and worldwide acceptance of this treatment.
